More American teens are being prescribed Wegovy, a weight-loss drug that mimics a hormone to regulate appetite, as doctors and families grow more comfortable using medications to treat obesity in adolescents. While this signals growing acceptance of medical tools to tackle a complex and often lifelong health issue, experts caution that challenges around access, affordability, and long-term safety persist.Sharp Rise in Teen PrescriptionsWegovy was approved by the U.S. Food and Drug Administration (FDA) in late 2022 for children aged 12 and older who are living with obesity. Since then, prescriptions have surged. According to health data company Truveta, which reviewed medical records from 30 U.S. health systems, prescriptions for Wegovy among teens jumped by 50% in 2024—rising from 9.9 per 100,000 adolescents in 2023 to 14.8 per 100,000 in 2024. The first quarter of 2025 showed another increase, with the rate reaching 17.3 per 100,000.But these numbers are still small compared to the scale of the issue. Government data shows that 8 million U.S. teens—about 23% of those aged 12 to 19—are living with obesity, a number that has more than quadrupled since 1980. The condition raises long-term risks such as type 2 diabetes, heart disease, and liver disease.A Promising Tool, But Not a Cure-All“It’s promising that more young people are using these medications, but it’s still a very small percentage of patients with severe obesity that are getting access to them,” said Dr. Cate Varney, an obesity medicine specialist at the University of Virginia Health System, in an interview with NBC News. “When lifestyle changes alone are insufficient, we need these additional tools.”The American Academy of Pediatrics (AAP) updated its guidelines in 2023 to recommend that doctors consider GLP-1 medications, like Wegovy, for children 12 and older with obesity. GLP-1 drugs mimic the effects of a hormone that controls hunger and food intake. However, only Wegovy is FDA-approved for adolescents. Others, such as Ozempic and Zepbound, are not approved for teen weight loss, though they are being studied for future use.Safety, Access, and Insurance HurdlesDespite the increased use, concerns linger. Experts point out that there is limited long-term data on how these medications may affect a developing adolescent’s body. “These medications are likely to be needed for a very long time to maintain weight,” said Dr. Robert Siegel of Cincinnati Children’s Hospital. “And we only have a relatively short-term experience with them.”Insurance coverage also presents a significant barrier. Many health plans do not cover weight-loss drugs for teens and often deny coverage for complementary care such as visits to dietitians or behavioral counseling. At Nemours Children’s Hospital in Delaware, about 25% of teens in one obesity treatment program were prescribed Wegovy or a similar drug last year—almost double the number from 2023. Still, many could not access the drug due to insurance or concerns about side effects.What the Future HoldsNovo Nordisk, the maker of Wegovy, claims its trials found no negative effects on puberty or growth. Eli Lilly, which produces Zepbound, is conducting its own studies in teens and so far reports no adverse effects on growth or metabolism.“We are confident in the proven safety and efficacy of our GLP-1 medicines,” Novo Nordisk said in a statement. Still, both researchers and government officials, including U.S. Health Secretary Robert F. Kennedy Jr., stress the need for long-term studies to fully understand the impact of using these medications in young people.